Medchemica
 Medchemica Home Medchemica About Us Medchemica Services Medchemica News Medchemica Contact Medchemica Publications

About Us

Dr Al Dossetter

Joined Zeneca in 1999 after a PhD from Nottingham University and post-doctoral research at Harvard University.

His 13 years of experience in medicinal chemistry has been spread across oncology (hormonal and kinase inhibitors), inflammation (OA and RA, enzyme inhibitors and GPCR targets) and diabetes (obesity, GPCR and enzyme inhibitors).

His work at AZ has resulted in numerous pre-clinical candidates.

Dr Ed Griffen

Joined Zeneca in 1994 after a PhD from Imperial College and post-doctoral research at the University of Waterloo-Kitchener, Canada.

His 20 years of experience in medicinal chemistry has been spread across CNS/pain (GPCRs), anti-infectives (enzyme inhibitors) and oncology (kinases, proteases, phenotypic screening, radiometal anitbody conjugates).

A secondment into the computational chemistry group led to the development of globally used AZ internal data-mining and exploitation tools. His work at AZ has focused on early stage projects and method development. He is also the author of a medicinal chemistry primer, visiting lecturer at the University of Manchester, and AZ Bangalore.

Dr Andrew G Leach

Joined AstraZenceca as a computational chemist in 2003 after a PhD from the University of Cambridge in the group of Prof. S. V. Ley, and then as Fulbright scholar undertaking post-doctoral research at the University of California, in the group of Prof. K. N. Houk.

On returning to the UK, he joined AstraZeneca as a computational chemist working in the oncology and then cardiovascular research areas. He contributed to the development of two compounds that remain under active clinical study.